Literature DB >> 20308781

Statin users without an APOE-epsilon4 allele have increased insulin resistance.

Brian T VanFossen1, G Stennis Watson, Laura D Baker, Kristoffer W Rhoads, Brenna A Cholerton, Mark A Reger, Stephen R Plymate, Gerald Schellenberg, Suzanne Craft.   

Abstract

The present study examined the relationships among statin use, APOE genotype, and insulin resistance as measured by the homeostasis model assessment of insulin resistance (HOMA-IR) in healthy older adults. APOE epsilon4- (i.e., not having an epsilon4 allele) statin users had higher HOMA-IR values compared with epsilon4+/statin users (p=0.0169), and with non-users who were epsilon4- (p=0.0003) or epsilon4+ (p=0.0006). These results suggest that statin use may modulate insulin levels for individuals without an APOE epsilon4 allele.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308781      PMCID： PMC2945621          DOI： 10.3233/JAD-2010-1319

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN： 1387-2877            Impact factor:   4.472


  26 in total

1.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.

Authors:  Rita Peila; Beatriz L Rodriguez; Lenore J Launer
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

2.  Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension.

Authors:  M C Lansang; G H Williams; J S Carroll
Journal:  Am J Hypertens       Date:  2001-01       Impact factor: 2.689

3.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.

Authors:  M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen
Journal:  BMJ       Date:  2001-06-16

4.  Dietary fats and the risk of incident Alzheimer disease.

Authors:  Martha Clare Morris; Denis A Evans; Julia L Bienias; Christine C Tangney; David A Bennett; Neelum Aggarwal; Julie Schneider; Robert S Wilson
Journal:  Arch Neurol       Date:  2003-02

5.  Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

Authors:  L M Refolo; B Malester; J LaFrancois; T Bryant-Thomas; R Wang; G S Tint; K Sambamurti; K Duff; M A Pappolla
Journal:  Neurobiol Dis       Date:  2000-08       Impact factor: 5.996

Review 6.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

7.  Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study.

Authors:  M D M Haag; A Hofman; P J Koudstaal; B H C Stricker; M M B Breteler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-10-17       Impact factor: 10.154

8.  Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype.

Authors:  Suzanne Craft; Sanjay Asthana; David G Cook; Laura D Baker; Monique Cherrier; Kristina Purganan; Colby Wait; Andreana Petrova; Shawn Latendresse; G Stennis Watson; John W Newcomer; Gerard D Schellenberg; Aaron J Krohn
Journal:  Psychoneuroendocrinology       Date:  2003-08       Impact factor: 4.905

Review 9.  Clinical significance of pleiotropic effects of statins: lipid reduction and beyond.

Authors:  J Auer; R Berent; T Weber; B Eber
Journal:  Curr Med Chem       Date:  2002-10       Impact factor: 4.530

Review 10.  Insulin and neurodegenerative disease: shared and specific mechanisms.

Authors:  Suzanne Craft; G Stennis Watson
Journal:  Lancet Neurol       Date:  2004-03       Impact factor: 44.182
View more
  3 in total

1.  Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China.

Authors:  Zhixiong Zhong; Heming Wu; Bin Li; Cunren Li; Zhidong Liu; Min Yang; Qifeng Zhang; Wei Zhong; Pingsen Zhao
Journal:  J Clin Lab Anal       Date:  2018-02-09       Impact factor: 2.352

2.  Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.

Authors:  Amy Claxton; Laura D Baker; Charles W Wilkinson; Emily H Trittschuh; Darla Chapman; G Stennis Watson; Brenna Cholerton; Stephen R Plymate; Matthew Arbuckle; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 3.  Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease.

Authors:  Ningnannan Zhang; Xiaowei Song; Robert Bartha; Steven Beyea; Ryan D'Arcy; Yunting Zhang; Kenneth Rockwood
Journal:  Curr Alzheimer Res       Date:  2014-05       Impact factor: 3.498
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.